|
Tobramycin inhalation powder versus Tobramycin inhalation solution for cystic fibrosis |
Hernández-Vásquez A, Pichon-Riviere A, Augustovski F, Ciapponi A, García Martí S, Alcaraz A, Bardach A, López A, Rey-Ares L |
|
|
Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Hernández-Vásquez A, Pichon-Riviere A, Augustovski F, Ciapponi A, García Martí S, Alcaraz A, Bardach A, López A, Rey-Ares L. Tobramycin inhalation powder versus Tobramycin inhalation solution for cystic fibrosis. Buenos Aires: Institute for Clinical Effectiveness and Health Policy (IECS). Documentos de Evaluación de Tecnologías Sanitarias, Informe de Respuesta Rápida N° 447. 2015 Authors' objectives To assess the available evidence on the efficacy, safety and coverage related aspects among different inhalation tobramycin formulations in patients with cystic fibrosis.
Cystic fibrosis (CF) is an autosomal recessive genetic disorder caused by a CFT (Cystic Fibrosis Transmembrane Conductance Regulator) gene disorder, affecting approximately 1 every 2,000-3,000 newborns in Europe and 1 every 3,500 newborns in the US. This disorder causes exocrine gland dysfunction, thus resulting in a significant inflammatory response in the airways, abnormal mucus, obstruction and tissue damage, favoring bacterial growth. Pseudomonas aeruginosa is one of the main colonizing pathogens and the most important cause of morbidity and mortality in this condition; therefore its eradication is very important to improve disease prognosis. Among the three routes of antibiotic administration (oral, inhalation and intravenous), inhalation is an attractive alternative for the treatment of lung infections, since it provides high local concentrations and it reduces systemic exposure. Authors' conclusions There is moderate quality evidence, including a single study comparing both inhalation modes. No significant differences were found in clinically significant results between tobramycin inhalation solution and tobramycin inhalation powder. The clinical practice guidelines and coverage policies found do not consider tobramycin inhalation powder as a first line treatment and in some cases, they mention it as a treatment alternative only under certain conditions such as intolerance or no response to colistin solution, colistin powder or tobramycin inhalation solution; and with price reduction agreements that make tobramycin inhalation power more affordable. Final publication URL www.iecs.org.ar Indexing Status Subject indexing assigned by CRD MeSH Cystic Fibrosis; Humans; Pseudomonas Infections; Pseudomonas aeruginosa; Tobramycin Language Published Spanish Country of organisation Argentina English summary An English language summary is available. Address for correspondence Institute for Clinical Effectiveness and Health Policy, Viamonte 2146 - 3 Piso, C1056ABH Ciudad de Buenos Aires, Argentina Tel: +54 11 49 66 00 82 Fax:+54 11 49 53 40 58 Email: info@iecs.org.ar AccessionNumber 32016000894 Date abstract record published 03/08/2016 |
|
|
|